Member Info for Wildforce

“”We do not want to live in a world in which we must develop and administer new boosters every time a new, dangerous COVID variant emerges. If you accept that hypothesis, then you should agree that we need better, more broadly protective, more durable COVID vaccines. And if we want them, we will need, collectively, to invest in the research and development to produce them. This should be a matter of the greatest urgency, and something we pursue even as we do everything we can to deploy the vaccines that we have to greatest effect.“”

Take care all ..

Happy new year all !!

It is strange how we are still in the dark about this trade ?

I can’t think of a reason why it hasn’t been notified !?

Take care all and fingers crossed for a great 2022 !!

Interesting that Redmile’s holding is circa 241 million shares … if it was them , leaves them a nice round number .. ish !?

But yes, the ‘buyer’ might be of interest .. this trade was not done on the open market (assuming it’s not cancelled! Lol ) ..

Take care all.

Quick message to say hope you all have a peaceful Christmas and I wish you all a successful 2022 !

Best wishes and take care! Wild ..

Morning all ! Thanks for the link .. interesting ‘conclusion’.

Take care ..

The world will need several next generation vaccines to tackle this predicament successfully … Scancell is in the right place at the right time in my opinion ! (Data permitting of course) ..

Take care ..

The BBC isn’t what it used to be in my opinion .. I watched a bit of bbc news 24 over the weekend and was dismayed when one of their political correspondents (AF) .. spent 5 minutes telling us all the options about what ‘might’ happen to Boris Johnson in the New Year !!!! Is that really ‘news’ !? Very poor ‘reporting’ !

Anyway .. interesting times at scancell !

Take care all !

Interesting research and some caveats noted ..

“ However, if new SARS-CoV-2 variants arise with mutant spike proteins that are poorly recognized by antibodies, T cell responses could become much more significant in the rational design of vaccines.”

Take care ..

Thanks for that heads up !

Good article !

Take care ..

There are a few in early stage development … found this short article interesting ..

https://www.google.co.uk/amp/s/www.precisionvaccinations.com/2021/12/10/where-are-2nd-generation-covid-19-vaccines%3famp

Take care all ..

If it cheered anyone up that’s great .. but was just posting my thoughts where we are with Covidity!

.. and yes, modi1 first patient dosed might not be too far away too !??

Take care .

It’s now over ten weeks since the first doses of Covidity were given .. understandably with new cutting edge clinical trials they have to start very slowly due to safety considerations.

As immunobody targets the immune system and the immune system acts fairly quickly .. it is comforting as a shareholder and as someone who believes the current vaccines arnt the end of the vaccine story that there is no report of ‘off target’ complications … that leaves the big question .. is the ‘on target’ science working … time will tell , they are screening for it !
And, it did with Scib1 !

Take care all !

On listening to it again .. I do get your point.

It’s the best data to come out of scancell so far as it is anyway, so I’ll leave it at that …

Take care ..

Finally got around to watching LD’s presentation ..

One takeaway from it and information we didn’t know is that LD commented on the 16 Scib1 resected stage 3/4 melanoma patients … to date the ten who were disease free at the end of the study still are !!!! And the four who were still alive at the end but had recurrence are also still alive !!

I wasn’t expecting to hear much more about these patients so that’s a great bit of news to hear !

(At about 1hr and 16mins or there abouts)

Take care all ..

Not just looking at ‘safety’ .. although it is the primary focus …

“””
Secondary Outcome Measures :
The immunogenicity of COVIDITY as assessed by antibody response [ Time Frame: From enrolment through end of study; approximately 26 weeks ]
Quantitative COVIDITY-specific antibody responses measured by enzyme-linked immunosorbent assay (ELISA) or using the Meso Scale Discovery (MSD) platform.

The immunogenicity of COVIDITY as assessed by seroconversion [ Time Frame: From enrolment through end of study; approximately 26 weeks ]
The proportion of participants who seroconvert (defined as a 4-fold change in COVIDITY-specific antibody titre from baseline).

The immunogenicity of COVIDITY as assessed by T cell response [ Time Frame: From enrolment through end of study; approximately 26 weeks ]
Quantitative COVIDITY-specific T cell responses measured by ELISpot assay.

“”” .

Take care all ..

Yes.. lol .. didn’t see your posts cos I was typing mine lol ..

Take care ..

Should Covidity do what it aims to … there won’t be ‘waning’ immunity like we are experiencing with the current vaccines .. The T-cell response produces a pool of memory cells with the ability to form a defence against secondary infection and so on ..

Along with targeting a more stable part of the virus, the response is a more sustained one too ! (If it goes as planned of course?) !

Take care all ..

Not had my ‘booster’ as yet as had my vaccines quite late .. might wait to take part in a clinical trial lol ..

Astra / Astra ……. Covidity !?

Take care all ..

All the initial vaccines were designed around the same target … the target is changing ?

Take care ..

Agree, as far as I’m aware the ‘boosters’ are the same vaccines. Only difference might be the ‘dose’ but other than that you are getting a top up of the same thing.

Take care..